Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign ...
Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint. Genentech said ...
These results underscore that fenebrutinib has potential as a high-efficacy oral treatment for RMS. Its unique mode of action may offer a differentiated profile by targeting dual drivers of MS within ...
Roche’s Genentech unit is launching a new multimedia campaign aimed at sharing the stories of people living with diabetes and ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...
Genentech’s Enspryng reduces risk of relapses by 68%; shows potential to become first treatment for MOGAD: South San Francisco, California Thursday, April 23, 2026, 15:00 Hrs [I ...
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...
Genentech is honing in on an aspect of the patient community that is too often overlooked — the role of caregivers in managing rare diseases. In a recently-released short film, Genentech tells the ...
Two more drug-making giants, Abbvie and Genentech, will start selling popular medications on the White House's discounted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results